Abstract
Pulmonary arterial remodeling is characterized by excessive proliferation, migration, and pro-differentiation and fibrotic activation of adventitial fibroblasts in pulmonary arterial hypertension (PAH) process. Several lines of evidence indicate that serotonin (5-HT) plays a central role in the pathogenesis of pulmonary arterial remodeling. In the present study, we investigated whether 5-HT is directly involved in the functional regulation of pulmonary artery adventitial fibroblasts (PAFs). Incubation of cultured rat PAFs with 5-HT caused a dose-dependent stimulation of cell proliferation, migration activity, and a time-dependent increase of α-SMA expression, a marker of fibroblast differentiation into myofibroblasts, and adventitia fibrosis, evaluating connective tissue growth factor (CTGF) and extracellular matrix (ECM) mRNAs and proteins. These effects were attenuated by the 5-HT2A receptor antagonist, ketanserin and mimicked by the 5-HT2A receptor agonist DOI. 5-HT-induced fibroblasts phenotypic alterations and ECM accumulation were dependent on stimulation of transforming growth factor (TGF)-β1 as demonstrated using a neutralizing antibody. 5-HT also caused Smad3 phosphorylation and ketanserin diminished 5-HT-induced Smad3 activation. These results demonstrated that 5-HT can directly activate PAFs through 5-HT2A receptor and promote fibroblasts phenotypic alterations and adventitia fibrosis depending on the signaling of the TGF-β1/Smad3 pathway.
Similar content being viewed by others
References
Taguchi K, Hattori Y (2013) Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension. Circ Res 112:227–229. doi:10.1161/CIRCRESAHA.112.300623
Shimoda LA, Laurie SS (2013) Vascular remodeling in pulmonary hypertension. J Mol Med (Berl) 91:297–309. doi:10.1007/s00109-013-0998-0
Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S–24S. doi:10.1016/j.jacc.2004.02.029
Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M, Riddle SR, Frid MG (2013) The adventitia: essential regulator of vascular wall structure and function. Annu Rev Physiol 75:23–47. doi:10.1146/annurev-physiol-030212-183802
Stenmark KR (2006) Role of the adventitia in pulmonary vascular remodeling. Physiology 21:134–145. doi:10.1152/physiol.00053.2005
Havelka GE, Kibbe MR (2011) The vascular adventitia: its role in the arterial injury response. Vasc Endovasc Surg 45:381–390. doi:10.1177/1538574411407698
Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR (2014) MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 114:67–78. doi:10.1161/CIRCRESAHA.114.301633
Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355–366. doi:10.1146/annurev.med.60.042307.110802
Hervé P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249–254. doi:10.1016/s0002-9343(99)80156-9
Kereveur A, Callebert J, Humbert M, Herve P, Simonneau G, Launay JM, Drouet L (2000) High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 20:2233–2239. doi:10.1161/01.atv.20.10.2233
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609–616. doi:10.1056/NEJM199608293350901
Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195:198–213. doi:10.1016/j.bbr.2008.03.020
Delaney C, Gien J, Grover TR, Roe G, Abman SH (2011) Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. Am J Physiol Lung Cell Mol Physiol 301:L937–L944. doi:10.1152/ajplung.00198.2011
Liu Y, Tian H, Yan X, Fan F, Wang W, Han J (2013) Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension. Exp Lung Res 39:70–79. doi:10.3109/01902148.2012.758191
Liu Y, Tian HY, Yan XL, Fan FL, Wang WP, Han JL, Zhang JB, Ma Q, Meng Y, Wei F (2013) Serotonin inhibits apoptosis of pulmonary artery smooth muscle cell by pERK1/2 and PDK through 5-HT1B receptors and 5-HT transporters. Cardiovasc Pathol 22:451–457. doi:10.1016/j.carpath.2013.03.003
Yabanoglu S, Akkiki M, Seguelas MH, Mialet-Perez J, Parini A, Pizzinat N (2009) Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol 46:518–525. doi:10.1016/j.yjmcc.2008.12.019
Sethi A, Jain A, Zode GS, Wordinger RJ, Clark AF (2011) Role of TGFβ/Smad signaling in gremlin induction of human trabecular meshwork extracellular matrix proteins. Invest Ophthalmol Vis Sci 52:5251–5259
Verrecchia F, Mauviel A (2002) Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211–215. doi:10.1046/j.1523-1747.2002.01641.x
Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106:1675–1680. doi:10.1161/CIRCRESAHA.110.217737
Biernacka A, Dobaczewski M, Frangogiannis NG (2011) TGF-beta signaling in fibrosis. Growth Factors 29:196–202. doi:10.3109/08977194.2011.595714
Welsh DJ, Scott PH, Peacock AJ (2006) p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia. Pulm Pharmacol Ther 19:128–138. doi:10.1016/j.pupt.2005.04.008
Welsh DJ, Peacock AJ, MacLEAN M, Harnett M (2001) Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care 164:282–289. doi:10.1164/ajrccm.164.2.2008054
Grewal JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL (1999) Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am J Physiol 276:F922–F930
Kim DC, Jun DW, Kwon YI, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS, Kim EK (2013) 5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis. Liver Int 33:535–543. doi:10.1111/liv.12110
Short M, Nemenoff RA, Zawada WM, Stenmark KR, Das M (2004) Hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts. Am J Physiol Cell Physiol 286:C416–C425. doi:10.1152/ajpcell.00169.2003
Tamura K (1997) Serotonin (5-hydroxytryptamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT2 receptors. Atherosclerosis 132:139–143. doi:10.1016/s0021-9150(97)00077-4
Durmowicz AG, Parks WC, Hyde DM, Mecham RP, Stenmark KR (1994) Persistence, re-expression, and induction of pulmonary arterial fibronectin, tropoelastin, and type I procollagen mRNA expression in neonatal hypoxic pulmonary hypertension. Am J Pathol 145:1411–1420
Mann DA, Oakley F (2013) Serotonin paracrine signaling in tissue fibrosis. Biochim Biophys Acta 1832:905–910. doi:10.1016/j.bbadis.2012.09.009
Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, Matsuda H, Kobori S, Shichiri M (1998) Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 54:1083–1092. doi:10.1046/j.1523-1755.1998.00114.x
Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jungel A, Beyer C, Kronke G, Zwerina J, Reiter R, Alenina N, Maroteaux L, Gay S, Schett G, Distler O, Distler JH (2011) Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 208:961–972. doi:10.1084/jem.20101629
Stenmark K, Frid M (2011) Pulmonary vascular remodeling: cellular and molecular mechanisms. In: Yuan JXJ, Garcia JGN, West JB, Hales CA, Rich S and Archer SL (eds) Textbook of pulmonary vascular disease, Springer US, pp 759–777
Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99:675–691. doi:10.1161/01.RES.0000243584.45145.3f
Acknowledgments
This study was supported by the National Natural Science Foundation of China (Grant No. 81170294) and the State Key Program of the National Natural Science Foundation of China (Grant No. 30830051).
Conflict of interest
None declared.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chen, C., Han, X., Fan, F. et al. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT2A receptors. Mol Cell Biochem 397, 267–276 (2014). https://doi.org/10.1007/s11010-014-2194-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-014-2194-0